Lifeward Ltd.
Lifeward is a medical device company that designs, develops and commercializes products for physical rehabilitation and recovery in clinical settings, homes and communities. Its products include the ReWalk Personal and Rehabilitation Exoskeletons for people with spinal cord injuries, the ReStore powered soft exo-suit for stroke rehabilitation, MYOLYN MyoCycle cycles, and AlterG Anti-Gravity systems, which use differential air pressure technology to support rehabilitation. The ReWalk Personal Exoskeleton is designed for everyday use, while the Rehabilitation Exoskeleton is configured for multiple users in clinics. Lifeward also develops related software, including Stride Smart for gait data and analysis. Lifeward sells primarily directly in the United States, through direct sales and distributors in Germany and Canada, and mainly through distributors in other markets. It generates revenue through sales to clinics, rehabilitation centers, distributors, third-party payors, sports teams and self-pay individuals. Its principal markets are the United States and Europe, with some sales in Asia, the Middle East and South America. Lifeward has primary offices in Yokneam, Israel, Hudson, Massachusetts, and Berlin, Germany.
No enriched coverage for $LFWD in the last 7 days.
No SEC Form 4 filings for $LFWD in the last 30 days.
See all $LFWD insider activity →Lifeward Ltd. (LFWD) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07 Submission of Matters to a Vote of Security Holders. An aggregate of 2,036,125 ordinary shares, no par value each (the “Ordinary Shares”), of Lifeward Ltd. (the “Company”), or approximately 71.7% of the 2,838,715 Ordinary Shares issued and outstanding as of September 30
Lifeward Ltd. (LFWD) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Appointment of Chief Financial Officer On October 26, 2026, the Board of Directors (the “Board”) of Lifeward Ltd. (the “Com
Lifeward Ltd. (LFWD) published a study on long-term use of its ReWalk Personal Exoskeleton, showing positive results in seven individuals with chronic paraplegia. The study, conducted by Andrea Giovanni Cutti and colleagues, reported no falls or fractures, with participants walking a median distance of 129 meters in a six-minute test. The exoskeleton is FDA-cleared and CE Marked, covered by Medicare for eligible beneficiaries.
Recent LFWD coverage spans corporate actions, financial news and technology.
The meeting outcomes confirm existing board composition and compensation policies, with one proposal rejected.
New CFO appointment with defined salary and bonus structure.
Positive clinical data may improve market perception and drive demand for ReWalk devices.
Management continuity risk rises while the company searches for a permanent CFO, which can pressure sentiment and increase governance uncertainty.
The unexpected CFO departure creates uncertainty about leadership and may pressure the stock.
AlphAI scores every news story that mentions LFWD with an AI model for sentiment and relevance, and aggregates insider trades from Lifeward Ltd.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Lifeward Ltd. (LFWD) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07 Submission of Matters to a Vote of Security Holders. An aggregate of 2,036,125 ordinary shares, no par value each (the “Ordinary Shares”), of Lifeward Ltd. (the “Company”), or approximately 71.7% of the 2,838,715 Ordinary Shares issued and outstanding as of September 30
Lifeward Ltd. (LFWD) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Appointment of Chief Financial Officer On October 26, 2026, the Board of Directors (the “Board”) of Lifeward Ltd. (the “Com
Lifeward Ltd. (LFWD) published a study on long-term use of its ReWalk Personal Exoskeleton, showing positive results in seven individuals with chronic paraplegia. The study, conducted by Andrea Giovanni Cutti and colleagues, reported no falls or fractures, with participants walking a median distance of 129 meters in a six-minute test. The exoskeleton is FDA-cleared and CE Marked, covered by Medicare for eligible beneficiaries.
Lifeward's CFO nominee, Rami Aviram, declined the position. Josh Hexter will continue as interim CFO. The company is searching for a permanent replacement.
Lifeward Ltd. (LFWD) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. As previously reported in Current Reports on Form 8-K filed with the Securities and Exchange Commission on August 31, 2026
Lifeward Ltd. (LFWD) named Josh Hexter as interim CFO effective October 1, 2026, following Almog Adar's departure. Hexter will serve until Rami Aviram's appointment on November 1, 2026. According to the company, Hexter also serves as interim CEO and will not receive additional compensation for the interim CFO role.
Lifeward Ltd. (LFWD) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. As previously disclosed in the Current Report on Form 8-K filed by Lifeward Ltd. (the “Company”) with the Securities and Ex
Lifeward Ltd. (LFWD) published a study showing its ReWalk exoskeleton improves daily activities, satisfaction, and reduces pain for spinal cord injury patients. All 12 participants performed kitchen activities, 10 did grooming. ReWalk sales rose 13% YoY to $2.5M in Q2 2026, with total LFWD revenue up 16% to $6.6M. LFWD stock is currently at $7.11, down 0.14%.
Oramed Pharmaceuticals (ORMP) has entered a milestone-based funding deal with Lifeward (LFWD), a maker of exoskeleton devices. Lifeward highlighted its strategic partnership with Oramed in an investor presentation, noting potential benefits and funding availability. The company aims to leverage robotics, AI, and reimbursement to grow in the rehabilitation market, with projections of significant market expansion by 2030.
Lifeward Ltd. (LFWD) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 NASDAQ: LFWD Platform to Restore Motion, Dignity, and Independence Transforming Rehabilitation. Changing Lives. Investor Presentation · September 2026 Forward - Looking Statements This presentation contains forward - looking statements within the meaning of Section 2
